Around the Helix: Cell and Gene Therapy Company Updates – July 24, 2024
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T
Of 724 patients treated at the center, the cumulative incidence of secondary hematologic malignancy at 3 years posttreatment was 6.5%.
CGTLive®’s Weekly Rewind – July 19, 2024
Review top news and interview highlights from the week ending July 19, 2024.
Sarcoma Awareness Month 2024: Looking Back at a Year of Progress for Cell and Gene Therapy
In observance of Sarcoma Awareness Month, held annually in July, we took a look back at the past year's news in cell/gene therapy for this cancer.
Biosyngen’s CAR-T Therapy BRG01 Cleared for Pivotal Trial in EBV-Positive Nasopharyngeal Carcinoma in China
BRG01 is engineered to target the EBV antigen, which is frequently expressed on nasopharyngeal carcinoma tumor cells.
Around the Helix: Cell and Gene Therapy Company Updates – July 17, 2024
